MIV THERAPEUTICS INC (OTCBB: MIVT)

Dear Reader,

MIV Therapeutics, Inc. (OTCBB:MIVT) today announced that it has received the Frost & Sullivan 2008 North America Technology Innovation Award in the field of interventional cardiology.  (Please See News Below).
 

Frost & Sullivan Best Practices Awards identify exemplary achievements within a multitude of industries and functional disciplines. The analysis on best practices that we conduct identifies companies, products, processes, and executives that have achieved world-class performances. This research is an invaluable source to companies for new ideas to improve strategies and processes, which ultimately drive corporate growth. These achievements are recognized with Frost & Sullivan Best Practices Awards.

MIV Therapeutics, Inc. is focused on commercializing the next generation of fully biocompatible coatings for cardiovascular stents and drug delivery systems to treat coronary artery disease, an estimated $6 billion worldwide market.

Breaking *News* From MIV Therapeutics Inc.

Press Release Source: MIV Therapeutics, Inc.
Monday February 25, 8:00 am ET

ATLANTA, GA--(MARKET WIRE)--Feb 25, 2008 -- MIV Therapeutics, Inc. (OTC BB:MIVT.OB - News) (Frankfurt:MIV.F - News), a leading developer of next-generation coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, today announced that the company received the Frost & Sullivan 2008 North America Technology Innovation Award in the field of interventional cardiology. Frost & Sullivan will present the award to Dr. Mark Landy, president and chief executive officer of MIV, at the 2008 Excellence in Medical Technologies & Life Sciences Awards Banquet on Wednesday, March 12, 2008 at the Hyatt Fisherman's Wharf in San Francisco.

"MIV Therapeutics has innovatively leveraged a polymer-free approach to tackle the present day limitations of first- and second-generation stents to develop a product characterized by excellent biocompatibility, flexibility, and optimal drug delivery," notes Pramodh Ishwarakrishnan, the Frost & Sullivan analyst who nominated MIV Therapeutics for the award.

"MIV Therapeutics is honored to receive this recognition from Frost & Sullivan for the advancements we are making in interventional cardiology," commented Dr. Landy. "The award acknowledges the importance of the future of advanced biocompatible coatings for drug-eluting applications using hydroxyapatite (HAp) on cardiovascular stents, as well as for a broad range of other implantable medical devices," Dr. Landy added.

About The Award
According to Frost & Sullivan, to identify the award recipient its analyst team tracks innovation in key hi-tech markets. The selection process includes primary participant interviews and extensive primary and secondary research via the bottom-up approach. The analyst team shortlists candidates on the basis of a set of qualitative and quantitative measurements. The analysts also consider the pace of research and technology innovation, and the significance or potential relevance of the innovation to the overall industry. The ultimate award recipient is chosen after a thorough evaluation of this research.

In addition to the methodology described above, there are specific criteria used to determine the final selection. The recipient of this award has excelled based on one or more of the following criteria:
 
--  Significance of the innovation(s) in the industry
--  Potential of the products of innovation(s) to become industry
    standard(s)
--  Competitive advantage of innovation vis-à-vis other related
    innovations
--  Impact (or potential impact) of innovation(s) on company or industry
    mind share and/or company bottom line
--  Breadth of intellectual property related to the innovation(s), that
    is, patents, scientific publications, and papers in peer-reviewed journals.

About MIV Therapeutics
MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting applications on cardiovascular stents, as well as for a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed to protect surrounding tissue from potentially harmful interactions with bare metallic stents. This coating platform is derived from hydroxyapatite (HAp), an organic material that has demonstrated excellent in vivo safety and biocompatibility. Hydroxyapatite is a porous material that makes up the bone mineral and matrix of teeth, and is widely used today as a bone substitute material and for coatings on implantable fixation devices in orthopedic, dental and other applications. The Company's novel polymer-free drug-eluting technologies based on HAp could also provide an attractive alternative to current polymer-based drug-eluting coatings on the stent market, which have been associated with undesirable effects. The Company's drug-eluting coatings are additionally designed to suit a broad range of implantable medical devices that could benefit from highly customizable drug release profiles. MIV Therapeutics has a Collaborative Research Agreement with the University of British Columbia and has received a government grant for its research program on the "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents," under the National Research Council-Industrial Research Assistance Program. Under this sponsorship, the Company is expected to complete its drug-eluting research and development program and to reach product commercialization. MIV's intellectual property portfolio includes patents held by the University of British Columbia and exclusively licensed to MIV. Key patent applications filed simultaneously in various countries around the world further protect the commercial exclusivity of MIV's inventions in the global marketplace. For more information, please visit www.mivtherapeutics.com.

About Frost & Sullivan
Frost & Sullivan, the Global Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnerships, visit http://www.awards.frost.com.

Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "proposed," "expected," "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties including, without limitation, the closing of the Share Purchase Agreement, the ability of the Company to raise sufficient funding and to continue to develop its various business interests as presently contemplated. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
     
Source: MIV Therapeutics, Inc.
 

About MIV Therapeutics Inc.

MIV has recently acquired Biosync Scientific in India and earlier, SagaX in Israel to significantly expand product offerings, as well as design, manufacturing and distribution capabilities.

Working since 2001 in close collaboration with The University of British Columbia (UBC), MIVT has developed a unique biocompatible nano-film coating that eliminates the side-effects attributed to current stent technology. This is a major breakthrough, which utilizes Hydroxyapatite (HAp), a mineral and major component of human bones and teeth, to protect surrounding arterial tissue from direct contact with bare metal stent. Comprehensive animal studies demonstrated Hydroxyapatite improves the performance of bare metal stents by inhibiting inflammatory responses, a common cause of restenosis, a re-growth of vascular tissue following stent implantation. 

MIVT announced the first ever human implantation of a hydroxyapatite-coated stent and the launch of the MIVT Pilot Trial.  The MIVT Pilot Trial will evaluate the safety and efficacy of MIVT’s polymer-free nanoscale microporous hydroxyapatite drug-eluting stent for the treatment of single de novo lesions in native coronary arteries.  The first procedure was conducted by Dr. Alexandre Abizaid of Institute Dante Pazzanese of Cardiology in Sao Paulo, Brazil. Dr. Abizaid and Institute Dante Pazzanes of Cardiology are among the world’s foremost experts in conducting clinical trials researching both new and existing drug-eluting stents. 

MIV Therapeutics announced on May 31, 2007: 

Start of Clinical Trial Marking First Ever Human Implantation of A Hydroxyapatite Coated Stent

The trial to study safety and efficacy of one of the company’s proprietary polymer – free drug eluting stent technologies

The beginning of human implantation represents the culmination of extensive research and development and a successful animal trial program. Human implantation represents a crucial milestone in MIVT’s strategic plan to develop a new class of polymer-free drug-eluting stents that could provide patients with superior outcomes.  "We are very pleased to announce that our human trials are underway in-line with our previous guidance," said Dr. Mark Landy, president of MIV Therapeutics. "We have worked diligently to create a new, novel technology that we expect will be an excellent alternative for millions of patients around the world suffering from coronary artery disease.

MIV Therapeutics is focused on commercializing the next generation of fully biocompatible coatings for cardiovascular stents and drug delivery systems to treat coronary artery disease, an estimated $6 billion worldwide market. The company's technologies are expected to offer a safer alternative to current drug-eluting stents and hope to solve the issues of late thrombosis.

MIVT’s polymer-free nanoscale microporous hydroxyapatite drug-eluting stent uses the Company’s GenX coronary stent system. The GenX stent is coated with one of MIVT’s proprietary hydroxyapatite polymer-free drug eluting systems that is 700 nanometers thin. 

This technology is not limited to stents and can be used on any implantable medical device including those in the orthopedic field. MIV also has a number of Non-Polymeric drug eluting coatings currently under development that are expected to offer a safer and possibly more effective solution to current products on the market. Human implantation of these technologies is also expected in 2007. 

MIVT’s current product portfolio encompasses the following preclinical development projects:

HAp-nano-film coating technology. MIVT's lead product in development is an HAp-coated coronary stent with a nano-film coating. HAp is naturally found in bone and tooth enamel and demonstrates complete biocompatibilty with the human body. As such, it may inhibit a variety of adverse and inflammatory reactions and potentially help reduce restenosis, a recurrence of CAD, Coronary Artery Disease, a re-blocking of arteries following angioplasty. It is also believed that HAp-coated cardiovascular stents, unlike their counterparts available at the global markets at the present time, will not trigger late adverse thrombogenic reactions. 

Drug-eluting stents. MIVT is expected to enter the drug-eluting stent market by using a thicker coating of HAp loaded with a suitable drug, i.e. anti-inflammatory. The technology has a variety of potential applications in cardiovascular and non-cardiovascular drug/device combination products, including peripheral stents, biodegradable implants, gene therapy, and delivery systems for release of chemotherapeutic agents. 

• Statistically, heart disease is the number one cause of mortality in North America
• 64 million-plus Americans suffer from cardiovascular disease
• Americans suffer over 1,000,000 known heart attacks each year
• Heart Disease and related care account for $329.2 billion and growing
• Women believe the greatest threat to their health is breast cancer (In reality, they are five times more likely to die of heart disease).

Other Recent News From MIVT

Press Release Source: MIV Therapeutics, Inc.
Monday November 12, 8:30 am ET

ATLANTA, GA--(MARKET WIRE)--Nov 12, 2007 -- MIV Therapeutics, Inc. (OTC BB:MIVT.OB - News) (Frankfurt:MIV.F - News)developer of next-generation coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, announces that the Drugs Controller General of India (DCGI), the governmental agency with regulatory authority over medical products, has approved two of the Company's bare metal stents for manufacture and sale in India.

The GenX(TM) Stainless Steel Coronary Stent & Stent System and the GenX(TM) CrCo Chromium Cobalt Coronary Stent & Stent System along with the company's additional angioplasty products will be officially launched into the Indian market at the Cardiological Society of India 59th Annual Meeting beginning December 5th to 9th in Hyderabad and will be available for sale in India through third party distributors.

Dr. Mark Landy, president of MIV Therapeutics, said, "This regulatory achievement permits MIV Therapeutics' entrée into one of the world's fastest growing stent markets with a highly competitive offering, and allows us to continue refining and increasing our manufacturing capability as we advance the clinical development of our unique drug-eluting stents using our advanced biocompatible coatings and drug delivery technology."

Coronary heart disease is a major health problem in India, one of the world's largest markets. According to a global study on cardiac diseases by the World Health Organization (WHO), India has the highest number of deaths from coronary heart disease in the world, exceeding 1.5 million in 2002. The WHO has predicted a cardiac epidemic for India by 2010.

"These two stents are designed to expand in a very controlled manner providing better vessel coverage. By expanding from the center outwards versus from the edges inwards they are designed to help reduce the injury caused during stent deployment and expansion. We believe they will help cardiovascular patients in India lead longer, healthier lives," concluded Dr. Landy.

The two stents are identical in design and performance with the main difference being strut thickness. The GenX(TM) Stainless Steel Coronary Stent has a strut thickness of 105 microns making it one of the thinnest-strut stainless steel stents available today. The GenX(TM) CrCo Chromium Cobalt Coronary Stent has a strut thickness of 65 micron, placing it amongst the thinnest-strut stents available today. Strut thinness has long been regarded as an important stent design feature as it reduces injury and aids re-endothelialization leading to lower restenosis and thrombosis rates.

You may view the entire news release HERE

Press Release Source: MIV Therapeutics, Inc.
Thursday November 8, 8:30 am ET

ATLANTA, GA--(MARKET WIRE)--Nov 8, 2007 -- MIV Therapeutics, Inc. (OTC BB:MIVT.OB - News) (Frankfurt:MIV.F - News) ("the Company"), a leading developer of next-generation coatings and advanced drug-delivery systems for cardiovascular stents and other implantable medical devices, announces that new data from a previously presented animal study comparing the safety and efficacy of the Company's Vestasync hydroxyapatite (HAp) coronary stent coating with low-dose Sirolimus to the Cypher® Stent showed less fibrinoid, a marker for delayed healing and equivalent efficacy. The data were presented at the American Heart Association's Scientific Sessions 2007 in Orlando, Fla. yesterday.

Lead researcher Helena M. van Beusekom of Erasmus MC in Rotterdam, The Netherlands, made an oral presentation entitled, "Hydroxy apatite coating eluting low dose sirolimus shows less delayed healing but equal efficacy to Cypher in Porcine Coronary Arteries." The data presented showed a statistically significant difference between an increase in Sirolimus and an increase in fibrinoid material, which is a strong indicator of delayed healing. In the presentation, the researchers concluded that "Hydroxyapatite is a safe coating and effectively releases Sirolimus. All dosages were equivalent to Cypher at 28 days, even at a four-fold lower dose and shows significantly less fibrinoid." The data are derived from an earlier study in porcine coronary arteries presented last year that concluded that HAp is a safe coating and effective in releasing Sirolimus.

Dr. Mark Landy, president of MIV Therapeutics, said, "Our VESTASYNC stent utilizes significantly less Sirolimus than the Cypher and we believe that our 55 µg dosage form is by far the lowest dose Sirolimus stent either available or in development. All three doses of Sirolimus tested in this animal study, produced significantly less fibrinoid material than Cypher. In our recent First-In-Man trial, we went one step further and demonstrated both safety and efficacy of the VESTASYNC in humans at four months, and look forward to starting a larger study shortly."

"Applying the findings from this study could help patients experience faster healing. This is another benefit of inert non-polymeric coatings such as HAp, compared with conventional drug-eluting stents that use polymers to attach the drug to the stent. It is our goal to develop a drug-eluting stent that does not produce the same response as the current generation of stents. These data are another confirmatory point in our endeavor to develop the safest possible drug eluting stent and clearly support the further development of our technology," concluded Dr. Landy.

Delayed healing is a well documented problem of the current generation of approved drug-eluting stents and could lead to an increase in thrombosis rate or an increased need for revascularization. In the study, there was a clear correlation between the amount of Sirolimus eluted and fibrinoid material.

Cypher is a registered trademark of Cordis Corporation.

You may view the entire news release HERE

Press Release Source: MIV Therapeutics, Inc.
Tuesday October 23, 7:30 am ET

ATLANTA, Oct. 23, 2007 (PRIME NEWSWIRE) -- MIV Therapeutics, Inc. (OTC BB:MIVT.OB - News) (Frankfurt:MIV.F - News), a leading developer of next-generation coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, announces that Alexandre Abizaid, M.D., Ph.D., Chief of Coronary Intervention of Institute Dante Pazzanese of Cardiology in Sao Paulo, Brazil, performed one live four-month follow-up case from the MIVT pilot trial at the Transcatheter Cardiovascular Therapeutics (TCT) 2007 conference yesterday, during which angiographic, IVUS and OCT studies were conducted. This patient represented the 14th follow-up patient in the 15-patient First-in-Man pilot study with the VESTASYNC Polymer-Free HAp-Coated Sirolimus-Eluting Stent. The 15th patient, who was a back-up patient, if required for this live case in the event that the 14th patient was unable to undergo the procedure, will be followed up shortly, bringing to a close the four-month follow-up of the study.

You may view the entire news release HERE
<<<Spacer>>>

Financial Highlights For  MIVT

To Contact MIV Therapeutics

1-8765 Ash Street - Vancouver, BC V6P 6T3 CAN
Website: http://www.mivtherapeutics.com

Investor Relations

Anthony Huston
604-301-9545 ext. 14
Toll-free: 800-221-5108 - Fax: 604-301-9546 
Email: investor@mivtherapeutics.com
 

MIVT is also traded on the Frankfurt, Germany stock exchange under the symbol MIV.

---

*** The Bull is Running. ***
There may never be a better time to feature YOUR company
to over 1 MILLION investors.

To learn more about our programs email us directly at info@stockupticks.com

Disclaimer: StockUpTicks.com is a property of Market Pathways Financial Relations Incorporated (MP).  The information, opinions and analysis contained herein are based on sources believed to be reliable but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. Past performance is no guarantee of future results. This report is a paid advertisement and is for information purposes only and should not be used as the basis for any investment decision.  MP has been paid twenty four thousand dollars by MIV Therapeutics Inc. for preparation and distribution of this report and other advertising services over a ninety day period. This constitutes a conflict of interest as to MP’s ability to remain objective in its communication regarding the subject company.  Write or call MP for detailed disclosure as required by Rule 17b of the Securities Act of 1933/1934 - Market Pathways 17595 Harvard Ave., Suite C519 Irvine, CA  92614.  MP is not an investment advisor and this report is not investment advice. This information is neither a solicitation to buy nor an offer to sell securities but is a paid advertisement.  Information contained herein contains forward-looking statements and is subject to significant risks and uncertainties, which will affect the results.  The opinions contained herein reflect our current judgment and are subject to change without notice. MP and/or its affiliates, associates and employees from time to time may have either a long or short position in securities mentioned.  Information contained herein may not be reproduced in whole or in part without the express written consent of Market Pathways Financial Relations Incorporated.